D5BL:F:F-Xtrackers - MSCI Europe Value UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 37.54

Change

0.00 (0.00)%

Market Cap

N/A

Volume

604.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-03 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.24 (-0.46%)

USD 128.40B
SXR8:F iShares Core S&P 500 UCITS ETF..

-2.20 (-0.39%)

USD 114.04B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.41 (-0.71%)

USD 108.41B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.07 (-0.46%)

USD 52.77B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 52.44B
VUSA:F Vanguard Funds Public Limited ..

-0.36 (-0.37%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

+0.03 (+0.44%)

USD 46.87B
0ZC:F Zscaler Inc

+3.55 (+1.37%)

USD 37.92B
BSND:F Danone SA

-0.10 (-0.68%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

-0.04 (-0.03%)

USD 24.77B

ETFs Containing D5BL:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.38% 88% B+ 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.38% 88% B+ 76% C+
Trailing 12 Months  
Capital Gain 15.58% 85% B 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.58% 83% B 65% D
Trailing 5 Years  
Capital Gain 96.34% 90% A- 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 96.34% 90% A- 62% D
Average Annual (5 Year Horizon)  
Capital Gain 13.02% 83% B 72% C
Dividend Return 13.02% 80% B- 64% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.86% 55% F 87% B+
Risk Adjusted Return 109.73% 97% N/A 96% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike